



Larry Kushi,  
ScD

Kaiser  
Permanente



Wendy  
Rubinstein,  
MD, PhD

ASCO  
CancerLinQ



Mark Walker,  
PhD

Concerto  
HealthAI



Ruth Pe Benito,  
MPH

Tempus



Mary Tran,  
MS

Syapse



Sean Khozin,  
MD, MPH

US FDA


Panel #1




Operationalizing the  
use of RWD

# Population Discussion

## Median and Lower/Upper Quartiles of Age at Index




## Stage of Patients with aNSCLC Per Treatment Category




# Outcomes: Overall Survival (OS)

rwOS




Median rwOS by category




# Outcomes: Time to Treatment Discontinuation (TTD)

## rwTTD



## rwTTD



# Future Directions

- Opportunities in Real World Data (RWD)
- Challenges associated with RWD
- How can RWD support RWE for FDA
- What is the role of RWD?

Thank you!